Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) Director Paul Maier sold 50,000 shares of the business's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Eton Pharmaceuticals Stock Down 4.6%
Shares of NASDAQ:ETON opened at $59.78 on Friday. The firm has a 50 day simple moving average of $45.17 and a 200 day simple moving average of $31.90. The company has a market cap of $1.71 billion, a PE ratio of 157.32 and a beta of 0.86. Eton Pharmaceuticals, Inc. has a 52 week low of $14.27 and a 52 week high of $66.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.19 by $0.24. The business had revenue of $37.59 million during the quarter, compared to analysts' expectations of $27.11 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. As a group, research analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.
Hedge Funds Weigh In On Eton Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Toth Financial Advisory Corp acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth about $43,000. Quarry LP bought a new position in Eton Pharmaceuticals in the third quarter valued at approximately $37,000. Persistent Asset Partners Ltd acquired a new stake in shares of Eton Pharmaceuticals during the second quarter worth $90,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Eton Pharmaceuticals during the 4th quarter worth about $44,000. Finally, Legal & General Group Plc acquired a new position in Eton Pharmaceuticals during the second quarter valued at approximately $41,000. Institutional investors and hedge funds own 27.86% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently commented on ETON shares. Wall Street Zen upgraded Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 13th. Zacks Research raised shares of Eton Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Craig Hallum increased their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, July 28th. Canaccord Genuity Group increased their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a "buy" rating in a research note on Friday, August 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $67.50.
Get Our Latest Report on ETON
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
